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Lisa Cosgrove, Ph.D.
Introduction

our role as healers, we work with

funding, and the majority of the individu-

Clinicians practic-

our patients to provide the exten-

als who serve as diagnostic panel mem-

ing today need to

sive informed consent that allows

bers also have drug industry ties. My

be aware of the

them to make knowledgeable deci-

colleagues and I discovered that 100% of

ways in which the

sions about using medications,

the individuals on two DSM panels,

current

given a thorough understanding of

Schizophrenia and Psychotic Disorders,

the cost/benefit ratio. (p. 3)

and Mood Disorders, had financial ties

industry-

dominated climate
may undermine the integrity of the scientific process and, thus, may compromise patient care. In the mental health
field, corporate sponsorship bias can
affect psychiatric taxonomy and clinical
Practice Guidelines (CPG).

Financial

conflicts of interest (FCOI) can occur
when there are financial associations
between researchers, authors, or panel
members developing psychiatric diagnostic and treatment guidelines, and the
pharmaceutical industry, or when randomized clinical trials (RCTs) are industry funded. Therefore, clinicians need to
be especially vigilant about the informed
consent process when patients are prescribed psychotropic medications. As
Past President, Elaine LeVine, Ph.D.
noted in the December, 2007 issue of

In order to be fully educated about the
risk/benefit ratio of psychotropic medications, we must critically evaluate the
diagnostic and treatment information
that is being produced and disseminated.
Psychiatric Taxonomy and the Pharmaceutical Industry
In 1952, the first official Diagnostic and
Statistical Manual of Mental Disorders
(DSM) was published by the American
Psychiatric Association. Few outside the
field had ever heard of what is now often referred to as the ―bible‖ of psychiatric disorders. Fewer still would have
predicted that 58 years later there
would be a firestorm of controversy
over the proposed revisions to the
DSM.

The Tablet, the issue of informed con-

In light of the DSM‘s clinical importance,

sent is a particularly salient one for Divi-

the appearance of industry bias, let

sion 55 members:

alone the reality, can undermine its in-

Psychologists adopting a scientistpractitioner model are in an excellent position to carefully analyze
the research regarding the efficacy
and safety of various drugs. Because we view education as part of

tegrity and weaken public trust. The
concern about undue industry influence
was heightened when it was discovered
that the organization that produces the
DSM, the American Psychiatric Association, receives substantial drug industry

(e.g., served on speakers‘ bureaus, corporate boards, received honoraria) with
the pharmaceutical industry (Cosgrove,
Krimsky, Vijayaraghavan, & Schneider,
2006). The fact that all of the members
of these panels had industry ties is problematic because psychopharmacology is
the standard treatment in these two
categories of disorders.
To its credit, the American Psychiatric
Association has required all DSM-V
panel members to post financial disclosure statements (http://www.dsm5.org).
Indeed, the American Psychiatric Association has made a commitment to better manage potential FCOI, and certainly this new disclosure requirement
appears to be a step in the right direction. One would, therefore, expect to
see a decrease in the number of individuals serving on the DSM-V panels
who have corporate ties. However, as
we reported in the New England Journal
of Medicine last year, despite increased
transparency, industry relationships with
DSM panel members persist; approximately 68% of the DSM-V task-force
members report having ties to the pharThe Tablet, November 2010
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maceutical

(Cosgrove,

to industry influence. Specifically, the

toms Syndrome" (http://www.dsm5.org).

Bursztajn, & Krimsky, 2009). This repre-

lack of biological markers opens the

This syndrome, proposed for inclusion

sents a relative increase of 20% over the

door for what some have referred to as

in the DSM-V, describes symptoms of

proportion of DSM-IV task-force mem-

―disease mongering‖ or ―widening the

psychosis that are theorized to appear

bers with such ties. But it is not only

boundaries

ill-

in individuals at risk for developing

task force members who have financial

ness‖ (Moynihan, Heath, & Henry,

schizophrenia, before they are actually

relationships with Big Pharma; of the

2002). In turn, this may allow pharma-

diagnosed with the disease. The idea is

137 DSM-V panel members who have

ceutical companies to apply for FDA

that if prodromal psychotic symptoms

posted disclosure statements, 77 (56%)

approval of new medications that are

are diagnosed and treated early enough,

reported industry ties, such as holding

actually ―me too‖ drugs, drugs that are

it will be possible to prevent at-risk indi-

stock

companies,

neither more efficacious nor safer than

viduals from developing schizophrenia

serving as consultants to the drug indus-

those already on the market. (See Egli

(Gobal, Cosgrove, & Bursztajn, in press).

try, or serving on drug company boards,

and Egli‘s excellent essay in the July,

However, the data do not support this

which is no improvement over the 56%

2007 Tablet on the FDA approval of

reasoning. Various studies have demon-

of DSM-IV members who were found to

Invega, then a new atypical antipsychotic

strated that only 16-30% of people with

have such industry relationships. Some

that is essentially a patent extender). In

symptoms of psychosis end up develop-

DSM-V panels still have a majority of

fact, sometimes the iatrogenic harms of

ing schizophrenia later in life (McGorry

members with industry ties. If financial

these medications may outweigh their

et al., 2009; Yung et al., 2008). More-

conflicts of interest are not reduced,

benefits.

over, it is not even clear that treatment

in

industry

pharmaceutical

of

treatable

private-sponsor bias in research will be
exacerbated.
With concerns mounting about the
American Psychiatric Association‘s financial ties with the pharmaceutical industry, questions have been raised by
patient advocacy groups, investigative

with antipsychotic medications reduces

“… the lack of biological
markers opens the door for
what some have referred to
as „disease mongering‟ or
„widening the boundaries of
treatable illness‟”

journalists, clinicians and researchers as

any more than treatment with placebo
(McGlashan et al., 2006). Based on these
findings, and in light of the adverse side
effects of antipsychotic medications,
including movement disorders, weight
gain, and diabetes, some researchers
have concluded that the risk/benefit

to whether the proposed changes for
the DSM-V are evidence-based. Because

My colleagues and I have been following

a DSM diagnosis influences treatment

the proposed revisions to the DSM. An

decisions, especially decisions about

example of a new disorder that expands

psychotropic medications, adding new

diagnostic boundaries and would likely

disorders can have a significant impact

result in an increase in the number of

on prescribing practices. Indeed, the

individuals

lack of biological markers for psychiatric

medication, especially children and ado-

conditions renders the field vulnerable

lescents, is "Attenuated Psychotic Symp-

The Tablet, November 2010

their risk for developing schizophrenia

prescribed

psychotropic

ratio does not justify treating those at
risk for psychosis with these medications (De Koning et al., 2009; McGorry
et al., 2009). We believe, therefore, that
before the DSM-V adopts "Attenuated
Psychotic Symptoms Syndrome," panel
members need to provide further…
(continued on pg. 62)
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(continued from pg. 61)
... evidence regarding the validity and
reliability of this newly proposed category (Gobal et al., in press).
Are clinical Practices Guidelines
(CPG) and Randomized clinical Trials
(RCTs) industry influenced?
As noted above, there are increasing
concerns that the pharmaceutical industry may be able to influence the defini-

Because meaningful informed consent

sults of RCTs. Researchers studying

requires a full representation of adverse

financial conflict of interest in clinical

effects and accurate information on the

trials of psychiatric medications found

efficacy of the recommended medica-

that, ―among the 162 randomized, dou-

tions, clinicians rely upon results of

ble-blind,

RCTs as the ―gold standard‖ for evi-

examined, those that reported conflict

dence-based medicine. Thus, it goes

of interest were 4.9 times more likely to

without saying that RCTs should be free

report positive results‖ (Perlis et al.,

of sponsor bias. However, in today‘s

2005). ―[T]he randomized trials agenda

climate, should clinicians be wary about

may need to reprogram its whole mis-

involvement (e.g., funding of clinical trials, guideline authors serving on speakers‘ bureaus of pharmaceutical companies) could affect CPG development. In
2009, my colleagues and I published the

ter understanding of harms‖ (Ioannidis,

“Results of these and other
studies have led some to
question whether financial
conflicts of interest and
marketing have triumphed
over science.”

results of a study that examined financial
associations between the pharmaceutical industry and authors of three major

studies

sion, including its reporting, toward bet-

tion of a mental health problem. There
also is the concern that drug industry

placebo-controlled

the ―evidence‖ being disseminated?

2009, p. 1739).
Results of these and other studies have
led some to question whether FCOI and
marketing have triumphed over science.
The under-reporting of negative results
and publication bias, leading to unsubstantiated efficacy and safety data, may
prevent clinicians from being able to

CPG for Bipolar Disorder, Major De-

Let‘s look at the recent research that

fully inform their patients about the as-

pressive Disorder and Schizophrenia.

addresses

sociated risks and benefits to taking a

We found that 90% of the authors had

Boutron, Ahmad, and Ravaud (2009)

financial ties to the pharmaceutical com-

examined reporting and presentation of

panies that manufactured the drugs that

harm-related results in RCTs published

were identified in the guidelines as rec-

in general medical journals with high-

ommended therapies for the respective

impact factors. They concluded that

mental illnesses; None of these financial

reporting of harms continues to be in-

associations were disclosed in the CPG

adequate. They found that information

(Cosgrove, Bursztajn, Krimsky, Anaya, &

related to the severity of adverse events

Walker, 2009). The results of this and

was not reported in 27.1% of RCTs, and

other studies highlight the need for

withdrawal of patients because of ad-

greater transparency and management

verse events was not reported in 47.4%

of FCOI in the development of CPG.

of RCTs. Another study also raises
questions

this

as

to

question.

whether

Pitrou,

clinicians

should unquestioningly accept the re-

recommended medication.
This is not to suggest that pharmaceutically-funded

researchers

intentionally

misrepresent their findings in a proindustry way. Researchers are not always aware of the subtle ways in which
their industry connections may influence
their choice of language or influence
their choice of which findings to highlight. It would also not be fair to say that
we can never trust industry-sponsored
research. In fact, some studies have
found that, ―the research methods of

The Tablet, November 2010
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trials sponsored by drug companies is at

astutely

pointed

out,

least as good as that of non-industry

training

in

scientist-practitioner

funded research, and in many cases bet-

model is essential in being able to care-

it" (1935/1994, p. 109). Prescribing psy-

ter‖ (Lexchin, Bero, Djulbegovic, &

fully and thoroughly assess the scientific

chologists take heed.

Clark, 2003, p. 1168). However, as this

evidence regarding the efficacy and

brief review of the literature shows,

safety

current disclosure requirements and the

However, this training needs to be aug-

peer-review process cannot ensure that

mented by incorporating a critical and

treatment recommendations published

reflective approach to psychiatric taxon-

in high-impact medical journals or pro-

omy, and to the treatment recommen-

duced by professional organizations will

dations disseminated in clinical Practice

be accurate, balanced, and free of cor-

Guidelines. Consideration of the role

porate sponsorship bias.

that the funding source may have played

medications.

reporting of results, is essential. For

The field of psychiatry has been plagued
by allegations that the pharmaceutical
industry may be exerting an undue influence on the profession. For example, in
2008 Senator Charles Grassley widened
his series of hearings and investigations
financial

psychotropic

in the research design, data analysis, or

Conclusion

into

of

the

psychologists‘

associations

between

medicine and the pharmaceutical industry by requiring the American Psychiatric Association to provide, ―an accounting of industry funding that pharmaceutical companies and/or the foundations
established by these companies have,
including but not limited to grants, donations, and sponsorship for meetings
or programs‖ (Moran, 2008).
The concerns about industry influence
in organized psychiatry make Division
55‘s goal of granting prescriptive authority to all properly trained psychologists
especially timely. As Dr. LeVine (2007)

The Tablet, November 2010

example, we must ask questions such as:
Were adequate outcome measures used
in this RCT? Was the effect size clinically
meaningful as well as statistically significant? Was equipoise violated by comparing the new medication to a placebo
rather than to a comparable drug already on the market? In terms of diagnosis, we must carefully examine the
evidence when new DSM diagnoses are
proposed or when changes in symptomatology are suggested, especially when
these changes will have a direct and
significant impact on prescribing practices.
Some psychiatrists have found it difficult
to understand how financial conflicts of
interest in the field may increase bias in
the diagnosis and treatment of mental
illness. As Upton Sinclair stated, "It is
difficult to get a man to understand

something when his salary depends
upon

his

not

understanding

Lisa Cosgrove, Ph.D. is a clinical psychologist and
associate professor in the Counseling Psychology
Department at the University of MassachusettsBoston. She is a Residential Research Fellow at
the Safra Center for Ethics, Harvard University
(AY 2010-2011). She is co-editor of Bias in
Psychiatric Diagnosis, and a contributing editor
of Psychiatric Ethics and the Rights of Persons with Mental Disabilities in Institutions
and the Community. Her work addresses the
ethical dilemmas that arise in the biomedical
field when there are financial ties between the
pharmaceutical industry and academic institutions or professional organizations.
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and Nurses to Improve the Reach

primary care practices. With them

and Quality of Primary Care. As

comes a new set of skills that can

the landmark health reform law

improve care and lower costs for

goes into effect, bringing millions of

patients with depression, physical

uninsured Americans onto insur-

disabilities, and other conditions

ance rolls over the next five years,

that have proven difficult to treat

demand for primary care services

in primary care settings….

will increase; So, too, will demand
for more accessible, effective, and
efficient models of primary care.
Rather than hiring more primary
care physicians, many medical practices, health centers, and other
primary care settings have been
experimenting with innovative
models of care that both extend
the reach of primary care physicians and increase the quality of
ambulatory services... [bringing]
pharmacists, social workers,
nurses, and nurse practitioners to

ments….
Dramatic Change Is Coming
Over the next five years, we will witness the systematic implementation of
what is perhaps the most significant social legislation enacted by the Congress
since the Great Society programs of

The Commonwealth Care Alliance

President Lyndon Johnson. Change is

invested heavily in the model –

definitely coming. This could well be an

spending approximately $4 million

extremely exciting era for our profes-

on 25 practices, many of which are

sion‘s prescribing psychologists. Those

located in low-income, safety net

with vision and perseverance will thrive

clinics.

and flourish.

The investment, which

covers the cost of hiring the nurse
practitioners by the primary care
practices and investing in infrastructure such as electronic medical records, is more than offset in
reductions in hospitalizations for
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2001 and the Division 55 Meritorious Service
Award in 2008.

preventable conditions as well as
delays in nursing home place-
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